查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2020213

免疫球蛋白市场规模、份额、成长及全球产业分析：按类型和应用划分，区域洞察及2026-2034年预测

Immunoglobulin Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 160 Pages | 商品交期: 请询问到货日

价格

免疫球蛋白市场成长要素

全球免疫球蛋白市场预计在2025年达到221.5亿美元，2026年成长至244.4亿美元，并在2034年达到436.8亿美元，预测期内复合年增长率（CAGR）为7.53%。北美地区在2025年占据市场主导地位，市占率达49.39%。这主要得益于免疫不全症盛行率的上升、完善的医疗保健基础设施以及创新产品的上市。

人类血浆来源的免疫球蛋白是治疗方法免疫力缺乏疾病、自体免疫疾病和其他慢性免疫介导疾病的重要手段。除了作为第一线疗法的应用日益广泛外，CSL（澳洲）、武田製药（日本）、Griffols（西班牙）和OctaPharma（瑞士）等主要企业持续加强研发投入，也是推动市场扩张的主要动力。监管机构的支持和新型免疫球蛋白产品的快速核准进一步巩固了市场的成长势头。

市场趋势

全球一个显着的趋势是皮下注射（SCIG）的普及。与静脉注射（IVIG）相比，SCIG具有许多优势，包括给药方便、安全性更高，以及患者可在家中自行注射。这一趋势有助于提高患者依从性并促进更广泛的应用。例如，2023年6月，Grifols公司在西班牙推出了浓度为20%的SCIG製剂XEMBIFY，旨在提高患者可及性并促进市场成长。

市场驱动因素

对原发性免疫力缺乏(PI)、慢性脱髓鞘多发性神经炎(CIDP)、Guillain-Barré二氏症候群和多灶性运动神经病变(MMN) 等免疫不全症治疗的需求不断增长，推动了免疫球蛋白市场的发展。随着这些疾病盛行率的上升，患者人数也随之增加，进而扩大了免疫球蛋白疗法的需求。根据《美国药剂师》杂誌2025年2月的报告，大约1-2%的美国人口将患有原发性免疫力缺乏症 (PIDD)。

市场限制因素

严格的政府监管是限制阻碍因素。免疫球蛋白源自血浆，必须符合严格的安全性、有效性和品质标准。美国食品药物管理局（FDA）等监管机构依据《公共卫生服务法案》（PHS法案）和《联邦食品、药品和化妆品法案》（FD&C法案）对血浆的采集、加工和分销进行监管。这些要求可能会限制市场快速扩张并增加生产成本。

市场机会

扩大生产能力蕴藏着巨大的成长机会。由于血浆供应和生产限制，供应链常常面临挑战。为了满足不断增长的需求，各公司正投资于高通量纯化系统、扩大分馏生产线并改进包装。 2025年2月，OctaPharma AG扩大了位于维也纳的生产设施，以提高人类血浆衍生药物的产量。

市场挑战

免疫球蛋白疗法的高成本是一项重大挑战。静脉注射免疫球蛋白（IVIG）和皮下注射免疫球蛋白（SCIG）疗法价格昂贵，导致病人自付费用高昂，且健保报销政策不尽相同。供不应求也加剧了价格上涨，限制了其普及应用。例如，挪威一项2024年针对重症肌无力患者的研究表明，接受IVIG治疗的患者在第一年的直接医疗费用是未接受治疗患者的2.3倍。

市场区隔

依产品类型：

  • 由于静脉注射免疫球蛋白（IVIG）在医院中的应用以及其在治疗严重神经免疫疾病方面的快速疗效，IVIG 在市场上占据主导地位。
  • 受自我给药的便利性和患者偏好的推动，SCIG预计将以11.18%的复合年增长率成长。

按剂型：

  • 到 2025 年，液体免疫球蛋白有望占据市场主导地位，因为它提供即用型配方，可降低污染风险和製备时间。
  • 预计在预测期内，冷冻干燥製剂的复合年增长率将达到 2.97%。

按最终用户划分：

  • 由于医院拥有完善的基础设施、病患监测和报销机制，因此占据了最大的份额。
  • 居家医疗预计将以 9.18% 的复合年增长率增长，这反映了 SCIG 疗法的日益普及。

区域展望

预计北美将引领市场，2025年市场规模将达114.6亿美元，2026年将达124.7亿美元。光是美国市场预计到2026年将达到111.9亿美元。

在政府援助和基础建设的支持下，预计欧洲市场将在2025年达到36.3亿美元，在2026年达到39.1亿美元。德国和英国市场预计在2026年将分别达到12.4亿美元和10.4亿美元。

预计亚太地区2025年的经济规模将达到33.8亿美元，2026年将达到37.1亿美元，其中日本和中国分别以14.1亿美元和21.2亿美元主导。印度预计2026年的经济规模将达到6.8亿美元。

预计拉丁美洲和中东及非洲市场将实现温和成长，到 2026 年，市场规模预计将分别达到 4.5 亿美元和 1.8 亿美元。仅海湾合作委员会地区预计将达到 3 亿美元。

目录

第一章：引言

第二章执行摘要

第三章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会
  • 市场趋势

第四章：主要考虑因素

  • 主要企业管道分析
  • 产业重大发展动态（合併、收购等）
  • 新产品发布：按主要企业划分
  • 主要国家/地区法规及还款状况概述
  • 主要国家/地区主要疾病的流行情况

第五章：2021-2034年全球免疫球蛋白市场分析、洞察与预测

  • 市场分析、洞察与预测：按产品类型划分
    • 静脉注射免疫球蛋白（IVIG）
      • 原发性免疫力缺乏
      • 次发性免疫力缺乏
      • 慢性脱髓鞘多发性神经炎
      • Guillain-Barré二氏症候群
      • 免疫性血小板缺乏紫斑症
      • 多灶性运动神经病变
      • 其他的
    • 皮下注射免疫球蛋白（SCIG）
      • 原发性免疫力缺乏
      • 次发性免疫力缺乏
      • 慢性脱髓鞘多发性神经炎
      • 其他的
  • 市场分析、洞察与预测：按形式
    • 液体
    • 冷冻干燥
  • 市场分析、洞察与预测：按最终用户划分
    • 医院
    • 诊所
    • 居家照护
  • 分析、洞察与预测：按地区划分
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第六章：北美免疫球蛋白市场分析、洞察与预测（2021-2034年）

  • 国家
    • 我们
    • 加拿大

第七章：欧洲免疫球蛋白市场分析、洞察与预测（2021-2034年）

  • 国家
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 斯堪地那维亚
    • 其他欧洲国家

第八章：亚太地区免疫球蛋白市场分析、洞察与预测（2021-2034年）

  • 国家
    • 中国
    • 日本
    • 印度
    • 东南亚
    • 澳洲
    • 其他亚太国家

第九章：拉丁美洲免疫球蛋白市场分析、洞察与预测（2021-2034年）

  • 国家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲国家

第十章：中东和非洲免疫球蛋白市场分析、洞察与预测（2021-2034年）

  • 国家
    • GCC
    • 南非
    • 其他中东和非洲国家

第十一章 竞争分析

  • 全球市占率分析（2025 年）
  • 公司简介
    • CSL
    • Takeda Pharmaceutical Company Limited
    • Grifols, SA
    • Kedrion SpA
    • Octapharma AG
    • ADMA Biologics, Inc.
    • Taibang Biologic Group（China Biologic Products Holdings, Inc.）
    • LFB Group
    • Shanghai RAAS Blood Products Co., Ltd
    • GC Biopharma Corp.
Product Code: FBI100571

Growth Factors of immunoglobulin Market

The global immunoglobulin market was valued at USD 22.15 billion in 2025 and is projected to grow to USD 24.44 billion in 2026, eventually reaching USD 43.68 billion by 2034, exhibiting a CAGR of 7.53% during the forecast period. North America dominated the market in 2025, holding a 49.39% share, driven by the rising prevalence of immunodeficiency diseases, strong healthcare infrastructure, and innovative product launches.

Immunoglobulins, derived from human plasma, are critical therapies for immunodeficiency disorders, autoimmune conditions, and other chronic immune-mediated diseases. Their growing use as first-line treatments and the ongoing R&D investment by leading pharmaceutical companies such as CSL (Australia), Takeda Pharmaceutical Company Limited (Japan), Grifols, S.A. (Spain), and Octapharma AG (Switzerland) are key factors driving market expansion. Regulatory support and expedited approvals for new immunoglobulin products further strengthen the market growth trajectory.

Market Trends

A prominent global trend is the shift toward subcutaneous administration (SCIG). SCIG provides multiple advantages over intravenous administration (IVIG), including easier administration, improved safety, and the ability for patients to self-administer at home. This trend supports higher patient adherence and broader adoption. For instance, in June 2023, Grifols, S.A. launched XEMBIFY, a 20% SCIG product in Spain to boost accessibility and growth.

Market Drivers

The rising demand for treatment of immunodeficiency diseases such as Primary Immunodeficiency (PI), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Guillain-Barre Syndrome, and Multifocal Motor Neuropathy (MMN) drives immunoglobulin market growth. The increasing prevalence of these conditions expands the patient population and, consequently, the demand for immunoglobulin therapies. According to a February 2025 report by the U.S. Pharmacist, approximately 1-2% of the U.S. population is affected by primary immunodeficiency disorders (PIDDs).

Market Restraints

Stringent government regulations act as a significant restraint. Immunoglobulins are plasma-derived and must meet strict safety, potency, and quality standards. Regulatory bodies such as the U.S. FDA monitor plasma collection, processing, and distribution under the Public Health Service (PHS) Act and Federal Food, Drug, and Cosmetic (FD&C) Act. These requirements can limit rapid market expansion and increase production costs.

Market Opportunities

Expanding manufacturing capacity presents a major growth opportunity. Plasma availability and production constraints often create supply chain challenges. Companies are investing in higher-throughput purification systems, expanded fractionation lines, and improved packaging to meet rising demand. In February 2025, Octapharma AG expanded its Vienna manufacturing facilities to increase production of human plasma-based medicines.

Market Challenges

The high cost of immunoglobulin therapies poses a critical challenge. IVIG and SCIG therapies are expensive, with high out-of-pocket costs and variable reimbursement policies. Supply shortages also contribute to higher prices, restricting adoption. For example, a 2024 study on Myasthenia Gravis patients in Norway showed that IVIG treatment resulted in 2.3 times higher direct medical costs in the first year compared to untreated patients.

Market Segmentation

By Product Type:

  • IVIG dominates the market due to hospital use and rapid onset of action for severe neuro-immunology conditions.
  • SCIG is expected to grow at a CAGR of 11.18%, driven by self-administration convenience and patient preference.

By Form:

  • Liquid immunoglobulin dominates in 2025, offering ready-to-use formulations that reduce contamination risk and preparation time.
  • Lyophilized form is projected to grow at a CAGR of 2.97% during the forecast period.

By End User:

  • Hospitals hold the largest share due to established infrastructure, patient monitoring, and reimbursement pathways.
  • Home care is projected to grow at a CAGR of 9.18%, reflecting the rising adoption of SCIG therapies.

Regional Outlook

North America led the market with USD 11.46 billion in 2025, projected to reach USD 12.47 billion in 2026. The U.S. market alone is expected at USD 11.19 billion in 2026.

Europe generated USD 3.63 billion in 2025, reaching USD 3.91 billion in 2026, driven by government support and infrastructure development. Germany and the U.K. markets are estimated at USD 1.24 billion and USD 1.04 billion, respectively, in 2026.

Asia Pacific accounted for USD 3.38 billion in 2025, projected to reach USD 3.71 billion in 2026, with Japan and China leading at USD 1.41 billion and USD 2.12 billion, respectively. India is expected at USD 0.68 billion in 2026.

Latin America and Middle East & Africa are projected to grow moderately, with market sizes of USD 0.45 billion and USD 0.18 billion, respectively, in 2026. The GCC region alone is expected to reach USD 0.30 billion.

Competitive Landscape

The market is highly consolidated with key players including CSL, Takeda, Grifols, Kedrion, Octapharma, ADMA Biologics, Taibang Biologic, LFB Group, Shanghai RAAS Blood Products, and GC Biopharma. Strategic partnerships, new product launches, and regulatory approvals are core strategies driving their market positions. Notable developments include Takeda's Orphan Drug Designation for mezagitamab in June 2025 and Grifols' IND submission for GRF312 in May 2025.

Conclusion

The global immunoglobulin market is poised for strong growth from USD 22.15 billion in 2025 to USD 43.68 billion by 2034, driven by rising immunodeficiency disease prevalence, innovative product launches, and expanding manufacturing capacities. While regulatory restrictions and high therapy costs pose challenges, technological innovations and strategic partnerships continue to propel the market forward.

Segmentation By Product Type, Form, End User, and Region

By Product Type * Intravenous Immunoglobulin (IVIG)

    • Primary Immunodeficiency
    • Secondary Immunodeficiency
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Guillain-Barre Syndrome
    • Immune Thrombocytopenic Purpura
    • Multifocal Motor Neuropathy
    • Others
  • Subcutaneous Immunoglobulin (SCIG)
    • Primary Immunodeficiency
    • Secondary Immunodeficiency
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Others

By Form * Liquid

  • Lyophilized

By End User * Hospitals

  • Clinics
  • Homecare

By Region * North America (By Product Type, Form, End User, and Country)

    • U.S.
    • Canada
  • Europe (By Product Type, Form, End User, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product Type, Form, End User, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product Type, Form, End User, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product Type, Form, End User, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Pipeline Analysis, By Key Players
  • 4.2. Key Industry Developments (Mergers, Acquisitions, etc.)
  • 4.3. New Product Launches, By Key Players
  • 4.4. Overview of Regulatory & Reimbursement Scenario, By Key Countries/Regions
  • 4.5. Prevalence of Major Diseases, By Key Countries/Regions

5. Global Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product Type
    • 5.1.1. Intravenous Immunoglobulin (IVIG)
      • 5.1.1.1. Primary Immunodeficiency
      • 5.1.1.2. Secondary Immunodeficiency
      • 5.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 5.1.1.4. Guillain-Barre Syndrome
      • 5.1.1.5. Immune Thrombocytopenic Purpura
      • 5.1.1.6. Multifocal Motor Neuropathy
      • 5.1.1.7. Others
    • 5.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 5.1.2.1. Primary Immunodeficiency
      • 5.1.2.2. Secondary Immunodeficiency
      • 5.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 5.1.2.4. Others
  • 5.2. Market Analysis, Insights and Forecast - By Form
    • 5.2.1. Liquid
    • 5.2.2. Lyophilized
  • 5.3. Market Analysis, Insights and Forecast - By End User
    • 5.3.1. Hospitals
    • 5.3.2. Clinics
    • 5.3.3. Homecare
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product Type
    • 6.1.1. Intravenous Immunoglobulin (IVIG)
      • 6.1.1.1. Primary Immunodeficiency
      • 6.1.1.2. Secondary Immunodeficiency
      • 6.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 6.1.1.4. Guillain-Barre Syndrome
      • 6.1.1.5. Immune Thrombocytopenic Purpura
      • 6.1.1.6. Multifocal Motor Neuropathy
      • 6.1.1.7. Others
    • 6.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 6.1.2.1. Primary Immunodeficiency
      • 6.1.2.2. Secondary Immunodeficiency
      • 6.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 6.1.2.4. Others
  • 6.2. Market Analysis, Insights and Forecast - By Form
    • 6.2.1. Liquid
    • 6.2.2. Lyophilized
  • 6.3. Market Analysis, Insights and Forecast - By End User
    • 6.3.1. Hospitals
    • 6.3.2. Clinics
    • 6.3.3. Homecare
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product Type
    • 7.1.1. Intravenous Immunoglobulin (IVIG)
      • 7.1.1.1. Primary Immunodeficiency
      • 7.1.1.2. Secondary Immunodeficiency
      • 7.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 7.1.1.4. Guillain-Barre Syndrome
      • 7.1.1.5. Immune Thrombocytopenic Purpura
      • 7.1.1.6. Multifocal Motor Neuropathy
      • 7.1.1.7. Others
    • 7.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 7.1.2.1. Primary Immunodeficiency
      • 7.1.2.2. Secondary Immunodeficiency
      • 7.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 7.1.2.4. Others
  • 7.2. Market Analysis, Insights and Forecast - By Form
    • 7.2.1. Liquid
    • 7.2.2. Lyophilized
  • 7.3. Market Analysis, Insights and Forecast - By End User
    • 7.3.1. Hospitals
    • 7.3.2. Clinics
    • 7.3.3. Homecare
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product Type
    • 8.1.1. Intravenous Immunoglobulin (IVIG)
      • 8.1.1.1. Primary Immunodeficiency
      • 8.1.1.2. Secondary Immunodeficiency
      • 8.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 8.1.1.4. Guillain-Barre Syndrome
      • 8.1.1.5. Immune Thrombocytopenic Purpura
      • 8.1.1.6. Multifocal Motor Neuropathy
      • 8.1.1.7. Others
    • 8.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 8.1.2.1. Primary Immunodeficiency
      • 8.1.2.2. Secondary Immunodeficiency
      • 8.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 8.1.2.4. Others
  • 8.2. Market Analysis, Insights and Forecast - By Form
    • 8.2.1. Liquid
    • 8.2.2. Lyophilized
  • 8.3. Market Analysis, Insights and Forecast - By End User
    • 8.3.1. Hospitals
    • 8.3.2. Clinics
    • 8.3.3. Homecare
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product Type
    • 9.1.1. Intravenous Immunoglobulin (IVIG)
      • 9.1.1.1. Primary Immunodeficiency
      • 9.1.1.2. Secondary Immunodeficiency
      • 9.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 9.1.1.4. Guillain-Barre Syndrome
      • 9.1.1.5. Immune Thrombocytopenic Purpura
      • 9.1.1.6. Multifocal Motor Neuropathy
      • 9.1.1.7. Others
    • 9.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 9.1.2.1. Primary Immunodeficiency
      • 9.1.2.2. Secondary Immunodeficiency
      • 9.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 9.1.2.4. Others
  • 9.2. Market Analysis, Insights and Forecast - By Form
    • 9.2.1. Liquid
    • 9.2.2. Lyophilized
  • 9.3. Market Analysis, Insights and Forecast - By End User
    • 9.3.1. Hospitals
    • 9.3.2. Clinics
    • 9.3.3. Homecare
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Immunoglobulin Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product Type
    • 10.1.1. Intravenous Immunoglobulin (IVIG)
      • 10.1.1.1. Primary Immunodeficiency
      • 10.1.1.2. Secondary Immunodeficiency
      • 10.1.1.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 10.1.1.4. Guillain-Barre Syndrome
      • 10.1.1.5. Immune Thrombocytopenic Purpura
      • 10.1.1.6. Multifocal Motor Neuropathy
      • 10.1.1.7. Others
    • 10.1.2. Subcutaneous Immunoglobulin (SCIG)
      • 10.1.2.1. Primary Immunodeficiency
      • 10.1.2.2. Secondary Immunodeficiency
      • 10.1.2.3. Chronic Inflammatory Demyelinating Polyneuropathy
      • 10.1.2.4. Others
  • 10.2. Market Analysis, Insights and Forecast - By Form
    • 10.2.1. Liquid
    • 10.2.2. Lyophilized
  • 10.3. Market Analysis, Insights and Forecast - By End User
    • 10.3.1. Hospitals
    • 10.3.2. Clinics
    • 10.3.3. Homecare
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
    • 11.2.1. CSL
    • 11.2.2. Takeda Pharmaceutical Company Limited
    • 11.2.3. Grifols, S.A.
    • 11.2.4. Kedrion S.p.A
    • 11.2.5. Octapharma AG
    • 11.2.6. ADMA Biologics, Inc.
    • 11.2.7. Taibang Biologic Group (China Biologic Products Holdings, Inc.)
    • 11.2.8. LFB Group
    • 11.2.9. Shanghai RAAS Blood Products Co., Ltd
    • 11.2.10. GC Biopharma Corp.

List of Tables

  • Table 1: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type, 2021-2034
  • Table 2: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 3: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 4: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 5: Global Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 6: Global Immunoglobulin Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 7: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 8: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 9: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 10: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 11: North America Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 12: North America Immunoglobulin Market Revenue (USD billion) Forecast, by Country, 2021-2034
  • Table 13: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 14: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 15: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 16: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 17: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 18: Europe Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 19: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 20: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 21: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 22: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 23: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 24: Asia Pacific Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 25: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 26: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 27: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 28: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 29: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 30: Latin America Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034
  • Table 31: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Product Type 2021-2034
  • Table 32: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Intravenous Immunoglobulin (IVIG), 2021-2034
  • Table 33: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Subcutaneous Immunoglobulin (SCIG), 2021-2034
  • Table 34: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Form, 2021-2034
  • Table 35: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by End User, 2021-2034
  • Table 36: Middle East & Africa Immunoglobulin Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Immunoglobulin Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Immunoglobulin Market Value Share (%), by Product Type, 2025 & 2034
  • Figure 3: Global Immunoglobulin Market Value Share (%), by Form, 2025 & 2034
  • Figure 4: Global Immunoglobulin Market Value Share (%), by End User, 2025 & 2034
  • Figure 5: Global Immunoglobulin Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 7: North America Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 8: North America Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 9: North America Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 10: North America Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 11: North America Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 12: North America Immunoglobulin Market Value (USD billion), by Country, 2025 & 2034
  • Figure 13: North America Immunoglobulin Market Value Share (%), by Country, 2025
  • Figure 14: Europe Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 15: Europe Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 16: Europe Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 17: Europe Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 18: Europe Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 19: Europe Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 20: Europe Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 23: Asia Pacific Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 24: Asia Pacific Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 25: Asia Pacific Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 26: Asia Pacific Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 27: Asia Pacific Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 28: Asia Pacific Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 31: Latin America Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 32: Latin America Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 33: Latin America Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 34: Latin America Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 35: Latin America Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 36: Latin America Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Immunoglobulin Market Value (USD billion), by Product Type 2025 & 2034
  • Figure 39: Middle East & Africa Immunoglobulin Market Value Share (%), by Product Type 2025
  • Figure 40: Middle East & Africa Immunoglobulin Market Value (USD billion), by Form, 2025 & 2034
  • Figure 41: Middle East & Africa Immunoglobulin Market Value Share (%), by Form, 2025
  • Figure 42: Middle East & Africa Immunoglobulin Market Value (USD billion), by End User, 2025 & 2034
  • Figure 43: Middle East & Africa Immunoglobulin Market Value Share (%), by End User, 2025
  • Figure 44: Middle East & Africa Immunoglobulin Market Value (USD billion), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Immunoglobulin Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Immunoglobulin Market Share (%), by Company, 2025